September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.
The results confirm the mechanism of action of the product VCN-01that replicatesand expresseshyaluronidase after intratumor injection in patients with pancreatic cancerresultingin reduction of tumor stiffness). In addition,VCN-01was also able toreach the tumorsand modify tumor matrix to favorimmune infiltrationafter systemic administration showing a good safety profile. Importantly, patients presentedevidences of clinical activitywhen VCN-01 was administered systemically in combination with the standard of care for pancreatic cancer. These data will bepresented in two separate posters:
•Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo, MD, PhD. Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain/ Div. of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10021.Abstract: #5465 / 459PPresentation time: Poster Area (Hall 4), Saturday, Sept. 28, from 12:00–13:00p.m.
•Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial.
Presenter: Rocio Garcia-CarboneroMD, PhD. Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainAbstract: #5185/ 710PPresentation time: Poster Area (Hall 4), Sunday, Sept. 29, from 12:00–13:00p.m.